Loading stock data…
ARGX
$783.50+1.78 (+0.23%)
Market ClosedLast close May 1
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
argenx SE in the Healthcare sector is trading at $783.50. The stock is currently 16% below its 52-week high of $934.62, remaining 0.4% above its 200-day moving average. Technical signals show neutral RSI of 42 and bearish MACD signal, explaining why ARGX maintains its current momentum and trend strength. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 42) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$783.50
Potential Downside
47.5%
Whystock Fair Value$411.22
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and imm...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$50.12B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
40.96
Beta
Defensive asset. Lower volatility than the S&P 500.
-0.09
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
17.48%
Volume
Today's trading volume
187,987
Recent News
High Growth Tech Stocks in Europe with Promising Potential
As European markets continue to digest corporate earnings and geopolitical developments, key indices such as the STOXX Europe 600 have shown positive momentum, reflecting a cautiously optimistic sentiment despite broader economic concerns like the IMF's trimmed eurozone growth forecast. In this context, identifying high-growth tech stocks with promising potential involves looking for companies that can leverage technological advancements and maintain resilience amid fluctuating market...
European Equities Traded in US as ADRs Ease in Thursday Trading
European equities traded in the US as American depositary receipts eased late Thursday morning with
European Equities Traded in the US as American Depositary Receipts Sharply Lower in Tuesday Trading
European equities traded in the US as American depositary receipts were falling sharply late Tuesday
A Look At argenx (ENXTBR:ARGX) Valuation After New VYVGART Data At The 2026 AAN Meeting
argenx (ENXTBR:ARGX) is back in focus after presenting new VYVGART data at the 2026 American Academy of Neurology meeting, highlighting efficacy in ocular myasthenia gravis and early clinical benefit signals in CIDP. See our latest analysis for argenx. argenx shares trade at €707.6 after a recent 21.0% 1 month share price return and 4.52% 7 day share price return. The year to date share price return is slightly negative, while longer term total shareholder returns, including reinvested...
The Bull Case For argenx (ENXTBR:ARGX) Could Change Following New VYVGART Ocular MG Efficacy Data
argenx SE recently presented new clinical data at the 2026 American Academy of Neurology meeting, showing VYVGART’s efficacy in ocular myasthenia gravis, broader generalized MG subtypes, and chronic inflammatory demyelinating polyneuropathy, alongside progress in its neuromuscular pipeline candidates adimanebart and empasiprubart. A key takeaway is that VYVGART became the first biologic to show efficacy specifically in ocular myasthenia gravis, supporting a planned supplemental FDA filing...